Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in mCRPC with PTEN Deletion
NCT06029998Phase 2Active, not recruiting
- Sponsor
- University of Utah
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Utah. Primary endpoint: Proportion of patients achieving PSA decline of >= 30% at 24 weeks. Started Mar 2024; status: active, not recruiting.
02
Drugs
bortezomib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06029998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06029998.